Soluble CD40 levels in plasma are associated with cardiovascular disease and in carotid plaques with a vulnerable phenotype by Shami, Annelie et al.
                                                                    
University of Dundee
Soluble CD40 levels in plasma are associated with cardiovascular disease and in
carotid plaques with a vulnerable phenotype











Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Shami, A., Edsfeldt, A., Bengtsson, E., Nilsson, J., Shore, A. C., Natali, A., Khan, F., Lutgens, E., & Gonçalve, I.
(2021). Soluble CD40 levels in plasma are associated with cardiovascular disease and in carotid plaques with a
vulnerable phenotype. Journal of Stroke, 23(3), 367-376. https://doi.org/10.5853/jos.2021.00178
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 08. Dec. 2021
Copyright © 2021  Korean Stroke Society
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which 
permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
pISSN: 2287-6391 • eISSN: 2287-6405
Original Article
http://j-stroke.org 367 
Soluble CD40 Levels in Plasma Are Associated with 
Cardiovascular Disease and in Carotid Plaques with a 
Vulnerable Phenotype
Annelie Shami,a Andreas Edsfeldt,a,b Eva Bengtsson,a Jan Nilsson,a Angela C. Shore,c Andrea Natali,d 
Faisel Khan,e Esther Lutgens,f,g,h Isabel Gonçalvesa,b
a Department of Clinical Sciences Malmo, Clinical Research Center, Lund University, Malmo, Sweden
b Department of Cardiology, Skane University Hospital, Lund University, Malmo, Sweden
c  Diabetes and Vascular Medicine, University of Exeter Medical School, National Institute for Health Research Exeter Clinical Research Facility, 
Exeter, UK
d Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
e Division of Molecular and Clinical Medicine, University of Dundee, Dundee, UK
f  Department of Medical Biochemistry, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam, 
Amsterdam, The Netherlands
g Institute for Cardiovascular Prevention (IPEK), Ludwig Maximilian University of Munich, Munich, Germany
h German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany
Background and Purpose CD40 and CD40 ligand (CD40L) are costimulatory molecules of the tu-
mor necrosis factor receptor superfamily and well known for their involvement in inflammatory 
diseases: atherosclerotic mouse models with disrupted CD40 signalling develop lesions of reduced 
size with a more stable plaque profile. This study investigated the potential of plasma and intra-
plaque levels of CD40 and CD40L as markers for cardiovascular disease (CVD) in humans and their 
association with plaque stability.
Methods Soluble CD40 and CD40L (sCD40L) were measured in plasma in 1,437 subjects from The 
SUrrogate markers for Micro- and Macro-vascular hard endpoints for Innovative diabetes Tools 
(SUMMIT) cohort. Intra-plaque levels of sCD40 and sCD40L were measured in atherosclerotic 
plaque homogenates from 199 subjects of the Carotid Plaque Imaging Project (CPIP) cohort.
Results Both plasma sCD40 and sCD40L levels were elevated in individuals with prevalent stroke, 
while sCD40 levels also were higher in individuals with a prior acute myocardial infarction. Plasma 
levels of sCD40 correlated with carotid intima-media thickness and total carotid plaque area and 
were associated with risk of cardiovascular events over a 3-year follow-up period. Intra-plaque 
levels of sCD40 and sCD40L were associated with plaque components characteristic for plaque 
vulnerability and extracellular matrix remodelling.
Conclusions Higher plasma sCD40 and sCD40L levels are associated with prevalent CVD. Plasma 
sCD40 levels also correlate with the severity of carotid atherosclerosis and predict future cardio-
vascular events, while intra-plaque levels correlate with a vulnerable plaque phenotype. Our find-
ings thus demonstrate that elevated levels of sCD40 and sCD40L are markers of CVD.
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Introduction
Cardiovascular disease (CVD) is the leading cause of mortality 
worldwide, accounting for 17.9 million deaths each year.1 The 
main underlying cause is atherosclerosis. Compromised stabili-
ty of atherosclerotic plaques results in thrombus formation, 
and, consequently, stroke or myocardial infarction (MI) de-
pending on the affected territory. Characteristics of a classical-
ly rupture-prone or vulnerable plaque include a thin fibrous 
cap, abundance of lipids, a prominent necrotic core and infil-
tration by immune cells, such as macrophages and T cells,2 
while eroded lesions are less inflamed and rich in proliferating 
smooth muscle cells (SMCs), proteoglycans and hyaluronan, 
and neovascularization.3 Ideally, ameliorating atherosclerosis 
involves two steps: (1) finding a reliable method to identify in-
dividuals with vulnerable plaques to start treatment in time to 
prevent ruptures—and subsequently symptoms, and (2) identi-
fying key players driving destabilization in rupture-prone 
plaques. Addressing both steps, this study not only evaluates 
the CD40/CD40L signalling dyad as a potential CVD marker but 
also explores its biological association with a vulnerable plaque 
phenotype.
CD40 and CD40 ligand (CD40L) are costimulatory molecules 
and members of the tumor necrosis factor (receptor) super-
family (TNF(R)SF).4 CD40 is expressed on a variety of immune 
and non-immune cells, including B cells, monocytes/macro-
phages, dendritic cells, SMCs and endothelial cells. CD40L is 
mainly expressed by activated T cells and platelets, but expres-
sion has also been described on B cells, as well as on endothe-
lial, epithelial, and SMCs5 CD40 signalling is propagated via 
adaptor proteins—the TNF receptor-associated factors6—and 
modulates a multitude of immunological responses.5 Athero-
sclerotic mouse models (apolipoprotein E [ApoE-/-], low-density 
lipoprotein receptor [LDLr-/-]) with disrupted CD40 signalling 
develop lesions of reduced size with a more stable plaque pro-
file, an effect achieved by CD40/CD40L knock out models, as 
well as by small molecule inhibitors and antibodies inhibiting 
the CD40 signalling pathway.6-9
 While not much is known about the specific actions of 
CD40 in human CVD, an association for CD40L in CVD has been 
suggested. Increased levels of platelet CD40L have been report-
ed in patients with hypercholesterolemia10 and plasma levels of 
soluble CD40L (sCD40L) were increased in patients with acute 
coronary syndromes.11 Furthermore, clinical evidence for in-
volvement of sCD40L in CVD include association with cardio-
vascular (CV) events in coronary artery disease,11 recurrent car-
diac events and future events in healthy women,12 carotid inti-
ma-media thickness (IMT) and hypertension,13 and via correla-
tions with other biomarkers of inflammation.14 A number of 
studies, however, have found no associations between plasma 
sCD40L and CVD15,16 or long-term CV (or all-cause) mortality.17 
Further clarification is thus essential to determine the value of 
sCD40L as a marker of CVD, and to investigate whether sCD40 
may be a useful complement or replacement biomarker.
To address the potential of sCD40 and sCD40L as markers of 
CVD, we have analysed plasma and carotid artery plaque levels 
of CD40/CD40L for associations with CV events, as well as ca-
rotid IMT and plaque vulnerability markers in two large human 
cohorts.
Methods
Extended methods are provided in the Supplementary Meth-
ods.
Study cohorts and samples
Plasma samples were included from 1,438 subjects (Figure 1) 
of the SUrrogate markers for Micro- and Macro-vascular hard 
endpoints for Innovative diabetes Tools (SUMMIT) study18 pop-
ulation, recruited between December 2010 and April 2013 from 
existing population cohorts and hospital registries at the uni-
versity hospitals in Malmö (Sweden), Pisa (Italy), Dundee and 
Exeter (UK).
 Carotid plaques (n=198) were collected from patients during 
carotid endarterectomies at the Vascular Department of Skane 
University Hospital (Malmö, Sweden) between 2005 and 2010 
(The Carotid Plaque Imaging Project [CPIP]).19 Immediately 
during surgery, removed plaques were snap-frozen in liquid ni-
Figure 1. Flow chart showing the study population of the The SUrrogate 
markers for Micro- and Macro-vascular hard endpoints for Innovative dia-
betes Tools (SUMMIT) cohort, including excluded subjects and subjects 
with/without cardiovascular disease (CVD).
1,500 The SUMMIT cohort
62 Subjects excluded due to 
insufficient sample quality
1,438 Study population
752 No CVD at baseline 
(53.3%)
686 CVD at baseline 
(47.7%)
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trogen. Histological analyses were performed on portions (1 
mm thick) cut from the most stenotic plaque region and em-
bedded in optimal cutting medium (Sakura Finetek Europe BV, 
Tokyo, Japan). Plaque homogenates were prepared from the 
rest of the plaques and used for all other plaque component 
quantifications. Clinical characteristics of the included patients 
are summarized in Supplementary Table 1. The studies were 
approved by the local ethical review boards and were carried 
out in accordance with the principles of the Declaration of 
Helsinki. There was no overlap between subjects of the two 
study cohorts.
Statistics
Shapiro-Wilk and D’Agostino-Pearson omnibus K2 tests were 
used to assess Gaussian distribution. Variables found to be nor-
mally distributed are shown as mean with standard deviation 
while non-normally distributed variables are shown as median 
with interquartile range (IQR). For analysis of plasma, plaque 
histology sections and homogenates, the Mann-Whitney U test 
was used to compare groups and Spearman’s rank correlation 
was used for continuous variables. For comparisons between 
categorical variables, the chi-square test was used. A logistic 
regression model was used to test for associations with CV 
events and mortality in the SUMMIT cohort. The model was 
adjusted for age, diabetes and prevalent ischemic stroke, acute 
myocardial infarction (AMI), and hypertension as covariates. A 
P-value of <0.05 was considered statistically significant. Sta-
tistical analysis was performed using SPSS version 26.0 (IBM 
Co., Armonk, NY, USA) and GraphPad Prism version 8.0.0 for 
Windows (GraphPad Software, San Diego, CA, USA, www.
graphpad.com). Adjustments for multiple comparisons were 
done when appropriate using the Holm-Šídák test.
Results
Plasma sCD40 levels are associated with stroke 
and acute myocardial infarction
To assess associations between sCD40, sCD40L and CVD, we 
analysed the plasma from 1,438 subjects from the SUMMIT 
cohort using Proximity Extension Assay (PEA). Comparatively 
high sCD40 levels were associated with prevalent ischemic 
stroke (P=3.0×10–5), MI (P=0.016), and hypertension 
(P=0.00021) (Table 1 and Supplementary Tables 2 and 3). The 
association with stroke remained after adjusting for age, dia-
betes, hypertension, and MI (odds ratio [OR], 1.5; 95% confi-
dence interval [CI], 1.084 to 1.959; P=0.013) and the associa-
tion with MI after adjusting for age, diabetes, hypertension, 
and stroke (OR, 1.2; 95% CI, 1.006 to 1.393; P=0.042). 
Similar to sCD40, higher plasma sCD40L levels were associ-
ated with prevalent stroke (P=0.020). However, sCD40L levels 
were not associated with hypertension or prevalent AMI, and 
associations did not remain after adjusting for the aforemen-
tioned confounders (stroke: OR, 1.1; 95% CI, 0.976 to 1.304; 
P=0.103; and MI: OR, 1.0; 95% CI, 0.968 to 1.125; P=0.270).
Plasma sCD40 levels are associated with carotid 
plaque burden and arterial stiffness
Plaque burden in the carotid artery was assessed via ultrasound 
imaging at study inclusion and we searched for possible asso-
ciations between sCD40 and sCD40L and plaque burden. A 
positive Spearman’s rank correlation was found between both 
plasma sCD40 and sCD40L levels and total plaque area 
(r=0.355, P<1×10–16 and r=0.409, P<1×10–16, respectively) (Ta-
ble 2). The association between sCD40 and sCD40L and carotid 
plaque burden was also reflected by positive correlations with 
Table 1. Spearman correlations between the circulating levels of sCD40 and sCD40L (arbitrary unit, SUMMIT cohort) and carotid plaque burden
Vascular ultrasound*
CD40 
(n=1,438 at inclusion; n=798 at follow-up)
CD40L 
(n=1,438 at inclusion; n=798 at follow-up)
r P P, adjusted† r P P, adjusted
Total plaque area‡ 0.355 <1×10–16 <1×10–16 0.409 <1×10–16 <1×10–16
Maximum plaque area (mm2) 0.322 <1×10–16 <1×10–16 0.340 <1×10–16 <1×10–16
No. of plaques, right carotid artery 0.354 <1×10–16 <1×10–16 0.152 2.0×10–8 1.0×10–7
No. of plaques, left carotid artery 0.398 <1×10–16 <1×10–16 0.142 1.9×10–7 7.6×10–7
Plaque length (mm) 0.316 <1×10–16 <1×10–16 0.286 1.3×10–15 9.3×10–15
Plaque height (mm) 0.223 5.9×10–10 1.2×10–9 0.164 0.000006 0.000018
Lumen diameter reduction (%) 0.129 0.00041 0.00041 0.224 5.2×10–10 3.1×10–9
Pulse wave velocity 0.247 8.0×10–8 <1×10–16 0.057 0.052 0.052
sCD40, soluble CD40; sCD40L, soluble CD40 ligand; SUMMIT, The SUrrogate markers for Micro- and Macro-vascular hard endpoints for Innovative diabetes 
Tools.
*Measured at study inclusion; †P-value adjusted for multiple comparisons; ‡Sum of all plaque areas/patient.
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overall number of plaques, measurements of plaque length, 
height and area, as well as with lumen diameter reduction (Ta-
ble 2).
Arterial stiffness—a well-known factor associated with ath-
erosclerosis progression20—was studied by pulse wave velocity 
at study inclusion. Plasma levels of sCD40, but not sCD40L, 
correlated with carotid arterial stiffness (r=0.247, P<1×10–16) 
(Table 2). Furthermore, sCD40 plasma levels measured at study 
inclusion showed a positive correlation with both mean and 
maximum IMT in the right and left common carotid artery 
(CCA), as well as in in the plaque bulb regions (Table 3). Associ-
ation was also found between plasma sCD40L and mean IMT 
in the bulb region of the right carotid artery (Table 3).
Plasma sCD40L levels are associated with carotid 
artery plaque progression and sCD40 levels with 
future cardiovascular events
To elucidate whether plasma sCD40 and sCD40L levels pre-
dicted carotid atherosclerosis progress, in addition to correlat-
ing with plaque burden at study inclusion, we compared the 
initial IMT measurements calculated via ultrasound imaging 
with IMT measurements taken after 3 years. Plasma sCD40L, 
but not sCD40, levels were associated with change—specifi-
cally plaque growth—in maximum IMT in the CCA and mean 
and maximum IMT in the bulb region of the plaques (Supple-
mentary Table 4). 
As sCD40L levels correlated with carotid plaque progression, 
we then investigated the potential for plasma sCD40 and sC-
D40L levels to predict future CV events using logistic regres-
sion. Interestingly, the level of sCD40, but not sCD40L, in plas-
ma was associated with the occurrence of fatal or non-fatal 
CV events during the 3 years follow-up period (OR, 1.3; 95% 
CI, 1.042 to 1.625) after adjusting for age, diabetes, hyperten-
sion as well as prevalent AMI and stroke at baseline (Table 3). 
Neither sCD40 nor sCD40L was associated with mortality (CV 
or all-cause). Considering sCD40 (with confounders age, diabe-
tes, hypertension as well as prevalent MI and stroke at base-
line) in a multiple logistic regression, the area under the curve 
Table 3. Logistic regression analysis of association between the circulating levels of sCD40 (sCD40, SUMMIT cohort) and cardiovascular events (adjusted for 
confounding factors*) (n=1,438)
Variable Confidence interval Odds ratio P
sCD40 1.042–1.625 1.3 0.020
Age 0.996–1.042 1.0 0.109
Diabetes 0.759–1.681 1.1 0.549
Hypertension 0.596–1.319 0.9 0.553
Acute myocardial infarction 1.178–2.467 1.7 0.005
Stroke 1.058–3.507 1.9 0.032
sCD40, soluble CD40; SUMMIT, The SUrrogate markers for Micro- and Macro-vascular hard endpoints for Innovative diabetes Tools.
*Odds ratios were adjusted for age (years) and prevalent diabetes, hypertension, prior acute myocardial infarction, and stroke (yes vs. no).
Table 2. Spearman correlations between the circulating levels of sCD40 and sCD40L (arbitrary unit, SUMMIT cohort) and IMT in the CCA and the carotid bulb 
region assessed by vascular ultrasound (measured at study inclusion)
IMT measurements 
CD40 
(n=1,438 at inclusion; n=798 at follow-up)
CD40L 
(n=1,438 at inclusion; n=798 at follow-up)
r P P, adjusted* r P P, adjusted
Right
Mean IMT in CCA 0.139 2.7×10–7 1.1×10–6 0.053 0.048 0.256
Max IMT in CCA 0.122 0.000006 0.000018 0.012 0.65 0.903
Mean IMT in bulb 0.234 1.4×10–16 6.6×10–16 0.081 0.005 0.039
Max IMT in bulb 0.268 <1×10–16 <1×10–16 0.077 0.008 0.055
Left
Mean IMT in CCA 0.088 0.001 0.0020 0.042 0.12 0.472
Max IMT in CCA 0.073 0.007 0.0070 0.000 0.99 0.990
Mean IMT in bulb 0.203 9.1×10–13 4.5×10–12 0.017 0.54 0.903
Max IMT in bulb 0.240 <1×10–16 <1×10–16 0.038 0.19 0.570
sCD40, soluble CD40; sCD40L, soluble CD40 ligand; SUMMIT, The SUrrogate markers for Micro- and Macro-vascular hard endpoints for Innovative diabetes 
Tools; IMT, intima-media thickness; CCA, common carotid artery.
*P-value adjusted for multiple comparisons.
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achieved was 0.629 (95% CI, 0.582 to 0.677), with sensitivities 
and specificities for varying cut-offs of the predicted values 
(10% to 90% quantiles) presented in Supplementary Table 5. 
CD40 and CD40L have similar expression patterns 
in human carotid plaques
To further explore the presence of CD40 and CD40L in athero-
sclerosis we examined their expression pattern in carotid end-
arterectomy plaques from the CPIP cohort (Figure 2). Immuno-
fluorescence staining was performed on sections obtained from 
the most stenotic plaque region. CD40 and CD40L expression 
was observed in several plaque parts, in particular in the shoul-
der and cap regions. Immunoreactivity was also found—though 
far less prominent—in the base of the plaque.
sCD40 is associated with a vulnerable plaque 
phenotype
To further explore the presence of CD40 and CD40L in athero-
sclerosis we examined their expression in homogenates from 
198 carotid endarterectomy plaques of the CPIP cohort (here 
Figure 2. CD40 and CD40 ligand (CD40L) localization in endarterectomy plaques. CD40 and CD40L immunoreactivity was found in particular in the shoulder 
(A, B) and cap (C, D) regions. Squares in insets mark enlarged plaque regions. Scale bars are 50 μm (far left and right image columns), 20 μm (middle column), 
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comprised of both the soluble and cell associated isoforms). 
Disrupted CD40 signalling in a murine atherosclerosis model 
results in increased stabilisation characterised by reductions in 
lipid core size and inflammatory cell presence accompanied by 
increased collagen content.6-9 We therefore investigated 
whether intra-plaque levels of these molecules are similarly 
associated with a vulnerable plaque profile in human lesions. 
Indeed, we found sCD40 plaque levels measured in plaque ho-
mogenates of the CPIP cohort to correlate with plaque compo-
nents collectively indicating a vulnerable plaque phenotype 
(Table 4). Accordingly, there was a correlation between sCD40 
and lipid content (visualized on tissue sections by Oil Red O, 
r=0.199, P=0.012; and oxidized low density lipoprotein [oxLDL] 
measured in plaque homogenate, r=0.236, P=0.004), whereas a 
negative correlation was found with calcium (von Kossa, r= 
–0.208, P=0.012). The level of sCD40L in plaque showed an 
overall association with a vulnerable plaque phenotype, albeit 
weaker than that for sCD40 levels (Table 4). sCD40L levels cor-
related with the plaque content of lipids (oxLDL measured in 
plaque homogenate, r=0.259, P=0.0037), while there was an 
inverse correlation with plaque levels of calcium (von Kossa, 
r=–0.268, P=0.00034). Finally, for further plaque profile evalu-
ation a vulnerability index was calculated, which was also 
found to correlate with both sCD40 (r=0.178, P=0.029) and 
sCD40L (r=0.180, P=0.041) plaque levels.
CD40 ligation has been previously well-described to induce 
pro-inflammatory cytokine and chemokines, including interleu-
kin (IL)-1β, IL-6, IL-8, IL-12, TNF-α, and chemokine (C-C motif) 
ligand 5 (CCL5) in vitro.21-23 Concordantly, sCD40 levels cor-
related with both IL-12p70 and CCL2 measured in plaque ho-
mogenate, as well as with several other inflammatory cyto-
kines and chemokines, including IL-6, TNF-α, CCL4, and C-X-C 
motif chemokine ligand 1 (CXCL1) (Table 4). Correlation was 
also found with platelet-derived growth factor (PDGF). Similar-
ly, sCD40L levels correlated with the inflammatory cytokines 
and chemokines IL-12p70, CCL2, IL-6, TNF-α, CCL4, CCL5, 
CXCL1 as well as with PDGF (Table 4).
sCD40 plaque levels are associated with features 
of extracellular matrix turnover
The reported increase in fibrous cap thickness and collagen 
content in plaques from CD40-deficient mice has been pro-
posed to result from the accompanying decreased plaque ex-
pression and activity of matrix metalloproteinase (MMP)-2 and 
-9 together with increased tissue inhibitor of metalloprotein-
ase (TIMP)-1 expression, and has thus prompted the suggestion 
that CD40 signalling destabilizes plaques by promoting extra-
cellular matrix (ECM) degradation and, as a result, fibrous cap 
thinning.6 Therefore, in this study we searched for similar asso-
ciations in human samples. Plaque levels of CD40 correlated 
with plaque content of MMP-1, -2, -9, and -10, while sCD40L 
levels correlated with only MMP-10 (Supplementary Table 6) 
Table 4. Spearman correlations of CD40 and CD40L (A.U., CPIP cohort) measured in plaque homogenate versus plaque elements
Variable
CD40 (n=198) CD40L (n=198)
r P P, adjusted* r P P, adjusted
Histology (area %)
Smooth muscle α-actin –0.070 0.33 0.33 –0.142 0.048 0.094
Calcium (van Kossa) –0.208 0.004 0.016 –0.268 0.00017 0.00068
Oil Red O 0.199 0.005 0.016 0.043 0.55 0.55
Vulnerability index† 0.178 0.014 0.029 0.180 0.014 0.041
Cytokines (pg/g)
CXCL1 0.228 0.002 0.012 0.268 0.002 0.008
IL-6 0.305 0.00032 0.0022 0.235 0.001 0.007
IL-12p70 0.211 0.004 0.020 0.230 0.002 0.008
Tumor necrosis factor α 0.391 3.4×10–8 3.1×10–7 0.290 6.9×10–5 0.0006
CCL5 0.021 0.772 0.772 0.200 0.007 0.014
CCL2 0.175 0.017 0.034 0.186 0.001 0.007
CCL4 0.202 0.006 0.020 0.186 0.011 0.014
PDGF-AA/AB/BB 0.268 0.0002 0.0018 0.243 0.001 0.007
Plaque components (mg/g)
oxLDL (μU/g) 0.236 0.001 0.004 0.259 0.00041 0.0037
CD40L, CD40 ligand; A.U., arbitrary unit; CPIP, Carotid Plaque Imaging Project; CXCL1, C-X-C motif chemokine ligand 1; IL, interleukin; CCL, chemokine (C-C 
motif) ligand; PDGF, platelet-derived growth factor; oxLDL, oxidized low density lipoprotein.
*P-value adjusted for multiple comparisons; †Calculated as (CD68++glycophorin A++Oil Red O+ area%) / (smooth muscle α-actin++collagen++von Kossa+ 
area%).
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Furthermore, both sCD40 and sCD40L levels correlated with 
TIMP-1 and TIMP-2. Thus, sCD40 (and CD40L) were indeed as-
sociated with plaque ECM turnover. Of note, correlations were 
also found between both sCD40 and sCD40L levels and content 
of intact elastin and collagen (type I–V) measured in plaque 
homogenate. 
Plaque sCD40 and sCD40L levels are not 
associated with pre-operative cerebrovascular 
symptoms
As sCD40 and sCD40L plasma levels were higher in subjects 
who had suffered a stroke in the SUMMIT cohort, we next an-
alysed whether sCD40 and/or sCD40L levels are similarly ele-
vated in the plaques from individuals after a cerebrovascular 
event (median time between symptom and surgery was 14 
days [IQR, 7 to 22]; the CPIP cohort). Levels of CD40 and CD40L 
measured in plaque strongly correlate with each other 
(r=0.613, P<0.0001) but neither sCD40, nor sCD40L levels cor-
related with the time between symptoms exhibited by the pa-
tients and the time of endarterectomy (r=0.04, P=0.688 and 
r=0.063, P=0.523, respectively). Also, plaque levels of sCD40 
and sCD40L were similar in plaques from asymptomatic and 
symptomatic patients (n=102 and n=96, respectively). 
Discussion 
With this study, we set out to assess the value of sCD40 as a 
possible marker of CVD and investigate the biological associa-
tions that support a role for CD40 in atherogenesis. Our find-
ings that sCD40 levels in plasma are associated with carotid 
plaque burden, while levels in carotid plaques are associated 
with a vulnerable plaque phenotype, strengthens the potential 
for sCD40 as marker for and mediator of CVD.
In contrast to the paucity of data in the literature for sCD40 
as a marker for CVD, sCD40L has been previously widely linked 
to CVD via increased levels in patients with hypercholesterol-
emia10 and acute coronary syndromes.11,24 Upregulated platelet 
surface expression of CD40L was also reported to correlate 
with worse clinical outcome after stroke25 and plasma sCD40L 
levels were higher in patients with carotid artery lesions that 
have intra-plaque lipid as detected by high-resolution magnet-
ic resonance imaging.26 Furthermore, Balla et al.27 identified se-
rum sCD40L levels as a risk factor for increased IMT in subjects 
with white-coat hypertension. Our current results are in line 
with these studies. 
Much less is known about the possible role of sCD40 as a 
marker for CVD. Though sCD40 appears to be actively produced 
under physiological conditions (as suggested by comparatively 
large amounts of sCD40 found in urine of healthy individu-
als),28 elevated plasma levels of sCD40 has nonetheless been 
described in pathologies such as systemic lupus erythemato-
sus,29 slow coronary flow phenomenon30 and early Alzheimer’s 
disease.31 In the SUMMIT cohort, we found higher plasma 
sCD40 levels in individuals that had suffered a prior ischemic 
stroke or MI or were hypertensive. Plasma sCD40 levels also 
correlated with carotid plaque burden and were associated 
with future CV events over a follow-up period of 3 years. We 
therefore propose sCD40 as a potential marker for the presence 
and severity of CVD. 
Efficient targeting of inflammatory processes can success-
fully stabilize vulnerable plaques in mice8,9 but this approach is 
not yet utilized in human disease beyond clinical trials32 due to 
detrimental side effects. In atherosclerotic mouse models dis-
rupted CD40 signalling—after blockade with antagonistic anti-
bodies, small molecule inhibitors and in CD40- and CD40L-de-
ficient mice—consistently results in plaques of reduced size 
and, importantly, a stabilized phenotype characterized by re-
duced lipid core content, macrophage and T-lymphocyte con-
tent accompanied by increased fibrous cap thickness, and rela-
tive collagen and SMC cell content.6-9 Previous studies explor-
ing CD40 signalling in relation to severity of inflammatory dis-
eases in humans have mainly focused on systemic levels of the 
signalling dyad, in particular levels of sCD40L and CD40L. This 
is the first study to also investigate associations between ca-
rotid intra-plaque CD40/CD40L content and plaque phenotype 
and disease progression. We found intra-plaque sCD40 (and to 
a certain extent also sCD40L) levels to be associated with a 
plaque profile rich in lipids, MMPs and pro-inflammatory cyto-
kines and chemokines: destabilising elements corresponding to 
those affected by blocking of the CD40/CD40L axis in mice.6-9 
This link between human disease and mouse model strength-
ens the merit of translating therapeutic targeting of CD40 
from the academic setting one step closer to the clinical appli-
cation.
Neither CD40 nor CD40L was associated with time between 
cerebrovascular symptoms and endarterectomy, suggesting 
they are not merely upregulated as part of the general healing 
response that occurs after plaque rupture. However, though 
sCD40 levels were associated with a less stable carotid plaque 
phenotype, plaque levels were nonetheless similar in plaques 
from symptomatic and asymptomatic patients. This inconsis-
tency may, at least in part, be explained by the accompanying 
association with components of the ECM turnover machinery, 
leading to a net effect in CD40-rich plaques, where enough 
ECM synthesis of stable plaque elements balances out the 
more vulnerable elements, resulting in a plaque phenotype still 
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stable enough not to rupture/erode and cause cerebrovascular 
symptoms. This in turn may indicate a local protective element 
in CD40-CD40L signalling, in addition to its well-described ac-
tions promoting the inflammatory process. We hypothesize 
that this may demonstrate the contrasting results of CD40 and 
CD40L interactions with (and in) different cell types of varying 
functions, such as macrophages, T cells, and SMCs in a model 
where CD40-signalling simultaneously for example promotes 
inflammation via macrophages and ECM synthesis via SMCs, 
even if the phenotypes of these cells have also been widely 
discussed.33 The therapeutic angle described by Seijkens et al.9 
of targeting CD40 signalling blockade specifically to macro-
phages (via incorporation into reconstituted high-density lipo-
proteins nanoparticles) therefore also emerges as an especially 
relevant approach to achieve plaque stabilisation.
Also interesting from a therapeutic standpoint is the study 
by Fernandez et al.,34 in which single cell RNA sequencing was 
compared in carotid plaques from patients who had or had not 
experienced cerebrovascular symptoms. Unexpectedly, the 
most upregulated pathways in T cells and macrophages from 
plaques from symptomatic patients were those of repair, while 
pro-inflammatory pathways were elevated in plaques from as-
ymptomatic patients. Repair pathways are thus deduced to be 
induced by plaque rupture, and therefore represent a less strik-
ing presence in plaques whose integrity is more intact. Conse-
quently, inflammatory activity weighs heavier in plaques from 
asymptomatic than from symptomatic individuals. This notion 
confirms the significance of our report that sCD40 is associat-
ed with vulnerable plaque components such as lipid content 
and pro-inflammatory cytokines, as well as with overall plaque 
burden, regardless of whether symptoms have manifested or 
not. Furthermore, the great success in ameliorating size and 
vulnerability of murine lesions (that are, per definition, 
pre-rupture) by blocking CD40 signalling affirms the value of 
targeting inflammatory responses in non-ruptured lesions. 
As limitations, it must be noted that correlations do not in-
dicate causality, and we cannot rule out that the reported as-
sociations may also result from an upregulation of sCD40 and 
sCD40L stimulated by an upstream signalling cascade or 
events. It is also important to bear in mind that in the plaque 
homogenates derived from the CPIP cohort it is not possible to 
distinguish between soluble and cell-bound CD40 and CD40L. 
The analysis thus shows the net effect of both isoforms, even if 
the effects of the individual isoforms may differ. Moreover, 
though it is impossible to be certain of the exact type of isch-
emic stroke, as subjects with atrial fibrillation were excluded in 
both cohorts, and—in the CPIP cohort—no signs of lacunar in-
farctions were found (assessed by brain computed tomogra-
phy), the probability of the underlying mechanisms to be atrial 
fibrillation and small vessel disease rather than atherosclerosis 
can be considered low. Unfortunately, the presence of cardiac 
valvular disease is impossible to exclude as not all patients un-
derwent echocardiography. Finally, as we in both cohorts mea-
sured sCD40L in plasma to evaluate its potential as a non-cell 
associated marker, platelet expression of CD40L—previously re-
ported e.g., by Cha et al.35 to be higher in subjects with athero-
sclerotic ischemic stroke than with asymptomatic carotid ste-
nosis—has not been taken into account.
Conclusions
In the present study we report for the first time elevated plas-
ma sCD40 levels in individuals with a prior ischemic stroke or 
MI, as well as an association with arterial stiffness, carotid 
plaque burden, and IMT, and, finally, an association with in-
creased risk of future CV events (Figure 3). Plasma levels of sC-
D40L are confirmed to not only be elevated in subjects after 
stroke, but also to correlate with future plaque progression in 
the form of IMT increase. We also present a novel association 
between intra-plaque levels of CD40 and CD40L and a vulner-
able plaque phenotype.
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Figure 3. Graphic representation of plasma soluble CD40 (sCD40) in car-
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The studies were approved by the local ethical review boards 
and were carried out in accordance with the principles of the 
Declaration of Helsinki. All study subjects provided written in-
formed consent. There was no overlap between subjects of the 
two study cohorts.
The SUMMIT
The SUrrogate markers for Micro- and Macro-vascular hard 
endpoints for Innovative diabetes Tools (SUMMIT) study1 pop-
ulation included 1,438 subjects recruited between December 
2010 and April 2013 from existing population cohorts and 
hospital registries at the university hospitals in Malmö (Swe-
den), Pisa (Italy), Dundee and Exeter (UK)—62 subjects were 
excluded (from the original cohort, n=1,500), due to insuffi-
cient quality of CD40/CD40L Proximity Extension Assay (PEA) 
results (Figure 1). Clinical characteristics of the included pa-
tients are summarized in Supplementary Table 1. Diabetes was 
defined by contemporary or historical evidence of hypergly-
caemia (according to World Health Organization 1998 criteria; 
fasting plasma glucose >7.0 mmol/L or 2-hour plasma glucose 
>11.1 mmol/L, or both) or by current medication with insulin, 
sulphonylureas, metformin or other anti-diabetic drugs. To de-
fine type 2 diabetes, patients should have been diagnosed after 
the age of 30. Subjects diagnosed <35 years of age or treated 
with insulin within 12 months of diagnosis were excluded. 
Classification of a clinical history of cardiovascular disease in-
cluded a previous diagnosis in the clinical record of non-fatal 
acute myocardial infarction (AMI), hospitalized unstable angi-
na, resuscitated cardiac arrest, any coronary revascularization 
procedure, non-fatal stroke, transient ischemic attack con-
firmed by a specialist, and lower extremities arterial disease 
(LEAD) defined as Ankle Brachial Pressure Index (ABPI) <0.9 
with intermittent claudication or prior corrective surgery, an-
gioplasty or above ankle amputation. Exclusion criteria includ-
ed renal replacement therapy, malignancy requiring active 
treatment, end-stage renal disease, any chronic inflammatory 
disease on therapy, previous bilateral carotid artery invasive 
interventions, or age <40 years. Additionally, subjects with 
atrial fibrillation were excluded. Demographics, clinical char-
acteristics including medication, physical and laboratory ex-
aminations were obtained according to a pre-defined study 
protocol at all four participating centers. 
The CPIP
Included in the Carotid Plaque Imaging Project (CPIP) study2 
were 198 carotid plaques collected from patients during carot-
id endarterectomies at the Vascular Department of Skane Uni-
versity Hospital (Malmö, Sweden) between 2005 and 2010. 
Clinical characteristics of the included patients are summarized 
in Supplementary Table 1. Blood samples were taken the day 
before endarterectomy. 
Surgery indications have been described previously.2 Briefly, 
symptomatic patients exhibited carotid artery stenosis (>70%) 
associated with ipsilateral symptoms, and asymptomatic pa-
tients exhibited carotid stenosis (>80%), but no ipsilateral 
symptoms 6 months prior to endarterectomy. Symptoms (i.e., 
amaurosis fugax, transient ischemia attack, or stroke) were 
evaluated by a neurologist and the stenosis degree was evalu-
ated by ultrasound based on flow velocities as previously de-
scribed.3 Patients with atrial fibrillation were excluded.
Immediately after surgery, removed plaques were snap-fro-
zen in liquid nitrogen. Histological analyses were performed on 
portions (1 mm thick) cut from the most stenotic plaque region 
and embedded in optimal cutting medium (Sakura Finetek Eu-
rope BV, Tokyo, Japan) and then sectioned (8 µm). Plaque ho-
mogenates were prepared from the rest of the snap-frozen 
plaques and used for all other plaque component quantifica-
tions as previously described.4
Plasma analysis
CD40 and CD40L were analysed in plaque homogenates from 
the CPIP cohort and in plasma from SUMMIT cohort using 
the PEA technique using the Proseek Multiplex CVD96x96 re-
agents kit (Olink Bioscience, Uppsala, Sweden) as described 
previously.5
The SUMMIT cohort: ultrasound imaging and 
evaluation of arterial stiffness
Atherosclerosis status was assessed via ultrasound imaging of 
the carotid arteries examining intima-media thickness (IMT) in 
the common carotid artery (CCA) and carotid bulb. Plaques 
were defined as focal thickenings (≥0.8 mm) of the artery wall. 
The length and height of each individual plaque were measured 
to calculate plaque area. The inter-observer variability of 
plaque area measurements was 8.9%±4.6%. The total plaque 
area represents the sum of the area all plaques identified in the 
left and right carotid arteries. Pulse wave velocity as an assess-
ment for arterial stiffness was calculated using a Sphygmocor 
device (Atcor Medical, Sydney, Australia). Methods were per-
formed as described previously.6 Change in mean and maximal 
IMT in the CCA and bulb (in mm) at the follow-up point is ex-
pressed as the measurements taken at inclusion subtracted by 
measurements taken at follow-up.
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The CPIP cohort: histology
Histological/immunohistochemical detection of Oil Red O, al-
pha smooth muscle actin, CD68,7,8 and glycophorin A9 was per-
formed as previously described on frozen tissue sections. Colla-
gen was visualized through a standard Russel-Movat penta-
chrome stain. For the Von Kossa calcium stain sections were 
fixed in 100% ethanol and then incubated in 1% silver nitrate, 
5% sodium thiosulfate, and 0.1% fast nuclear red. Between in-
cubations sections were rinsed in distilled H2O. Stained slides 
were scanned and digitalized using an Aperio ScanScope digi-
tal slide scanner (Aperio Technologies Inc., Vista, CA, USA). 
Quantifications were performed on blinded samples, using Bi-
oPix iQ version 2.3.1 imaging software (Biopix AB, Gothenburg, 
Sweden). Vulnerability index was calculated as
(CD68+)  + (Glycophorin A+)  + (Oil Red O+) area%
(Smooth muscle α-actin+) + (Collagen+) + (von Kossa+) area%
Paraffin-embedded sections from 22 subjects were used for 
immunofluorescence detection of CD40 and CD40L. Sections 
was deparaffinised and re-hydrated in a graded series of etha-
nol. Heat-induced epitope retrieval (pH 6) was performed prior 
to incubation with primary antibodies for 1 hour (CD40: 
ab13545, CD40L: ab2391; Abcam, Cambridge, UK). As a nega-
tive control an isotype control (ab27478, Abcam) of matching 
antibody concentration and host species was used. Sections 
were incubated with an Alexa 555-conjugated secondary anti-
body (ab150074, Abcam) for 1 hour and then mounted with a 
DAPI-containing mounting media (Vectashield Antifade 
mounting medium with DAPI, Vector Laboratories Inc., Burling-
tame, CA, USA). Images were taken using a Nikon Eclipse E800 
microscope (BergmanLabora, Danderyd, Sweden) with Olympus 
cellSens Standard 1.18 software.
The CPIP cohort: plaque component analyses on 
plaque homogenates
Multiplex analysis of cytokines (interleukin [IL]-6, IL-23p70, 
C-X-C motif chemokine ligand 1 [CXCL-1], chemokine (C-C 
motif) ligand [CCL]-2, -4, and -5, platelet-derived growth fac-
tor AA/BA/BB, and tumor necrosis factor-α) was performed us-
ing Luminex as previously described.9 Matrix metalloproteinas-
es (MMPs) -1, -2, -9, -10 and tissue inhibitor of metallopro-
teinases (TIMPs) -1, -2, and -3 were measured using the Meso-
scale human MMP ultra-sensitive kit (Mesoscale, Gaithersburg, 
MD, USA) and MILLIPLEX MAP Human TIMP Magnetic Bead 
Panel (Milliplex, Millipore Corporation, Billerica, MA, USA), re-
spectively, as previously described.9 Oxidized low density lipo-
protein was analysed by enzyme-linked immunosorbent assay 
(ELISA) as previously described.10 Collagen and elastin were 
quantified using the Sircol soluble collagen assay (Biocolor, 
Carrickfergus, UK) and the Fastin elastin assay (Biocolor), re-
spectively, as described previously.4 Results were normalized to 
plaque wet weight and all analyses were performed according 
to the manufacturer’s instructions.
Statistics
Shapiro-Wilk and D’Agostino-Pearson omnibus K2 tests were 
used to assess Gaussian distribution. Variables found to be nor-
mally distributed are shown as mean with standard deviation 
while non-normally distributed variables are shown as median 
with interquartile range. For analysis of plasma, plaque histolo-
gy sections and homogenates, the Mann-Whitney U test was 
used to compare groups and Spearman’s rank correlation was 
used for continuous variables. For comparisons between cate-
gorical variables, the chi-square test was used. Spearman’s 
rank correlation was chosen (over Pearson’s correlation test) 
due to the non-Gaussian distribution of the CD40 and CD40L 
variables and to account for monotonic as well as linear rela-
tionships between CD40L and the various parameters tested.
Subjects included in the SUMMIT cohort were followed up 
after 36 months at all four sites and information of cardiovas-
cular events were registered. Cardiovascular events were de-
fined as AMI (non-fatal or fatal), hospitalized unstable angina, 
cardiac arrest (resuscitated or fatal), any coronary revascular-
ization procedure, stroke (non-fatal or fatal), and transient 
ischemic attack confirmed by a specialist, LEAD defined as 
ABPI <0.9 with intermittent claudication or prior corrective 
surgery, angioplasty, or above ankle amputation. A logistic re-
gression model was used to test for associations with cardio-
vascular events and mortality during a follow-up. The model 
was adjusted for age, diabetes and prevalent stroke, AMI, and 
hypertension as covariates. The model was implemented in R 
using the rms package.11 Area under the receiver operating 
characteristics (ROC) curve and confidence intervals were esti-
mated by the pROC package12 with 2,000 stratified bootstrap 
replicates. To further examine performances of our proposed 
model in decision making, sensitivities and specificities with 
confidence intervals were estimated by the pROC package12 
with 2,000 stratified bootstrap replicates using varying cut-off 
values of the predicted values from the logistic regression. 
Considering that the costs of false positives and false negatives 
may vary in clinical applications, we examined sensitivities and 
specificities from 10% to 90% quantile of the predicted values. 
A high specificity level would be preferred if less false positives 
were expected.
A P-value of <0.05 was considered statistically significant. 
Statistical analysis was performed using SPSS version 26.0 
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(IBM Co., Armonk, NY, USA) and GraphPad Prism version 8.0.0 
for Windows (GraphPad Software, San Diego, CA, USA, www.
graphpad.com). Adjustments for multiple comparisons were 
done when appropriate using the Holm-Šídák test.
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Supplementary Table 2. Spearman correlations between sCD40 and sCD40L in plasma (arbitrary unit) and the subjects’ general clinical characteristics 
(SUMMIT cohort)
Variable
CD40 (n=1,438) CD40L (n=1,438)
r P P, adjusted r P P, adjusted
Age (yr) 0.399 <1×10–16 <1×10–16 0.234 <1×10–16 <1×10–16
Body mass index (kg/m2) 0.002 0.93 0.94 –0.124 0.000003 0.000018
Blood (mmol/L)
HbA1c (mmol/mol) 0.015 0.58 0.91 –0.006 0.81 0.85
f-Glucose 0.133 0.00025 0.0015 0.131 0.00033 0.0020
Total cholesterol –0.061 0.022 0.11 0.109 0.000039 0.00023
LDL –0.028 0.31 0.77 0.189 2.2×10–12 1.76×10–11
HDL –0.001 0.97 0.97 0.076 0.004 0.016
Triglycerides 0.015 0.56 0.91 –0.070 0.008 0.024
sCD40, soluble CD40; sCD40L, soluble CD40 ligand; SUMMIT, The SUrrogate markers for Micro- and Macro-vascular hard endpoints for Innovative diabetes 
Tools; HbA1c, hemoglobin A1c; LDL, low density lipoprotein; HDL, high density lipoprotein.
Supplementary Table 1. Patient demographics in the CPIP and SUMMIT study cohorts
Variable CPIP (n=198) SUMMIT (n=1,438) P P, adjusted*
At baseline
Sex (% female) 32 35 0.43 0.81
Age (yr)  70 (64.2–75.8) 68 (62–74) 0.0034 0.020
Body mass index (kg/m2) 27.3±4.1 28.6 (25.6–32.3) 1.9×10–12 2.1×10–11
Smoking, currently or in the past (%) 80 62 1.9×10–5 0.00015
Diabetes (%) 33 66 <1×10–16 <1×10–14
Hypertension (%) 75 67 0.028 0.11
Use of statins (%) 88 66 5.7×10–10 5.1×10–9
Under treatment (%)† 97 80 <1×10–16 <1×10–14
Fasting lipoproteins (mmol/L)
Total cholesterol 4.1 (3.5–5.1) 4.2 (3.6–5.0) 0.69 0.81
Triglycerides 1.4 (1–1.8) 1.3 (1.0–1.9) 0.50 0.81
LDL-C 2.4 (1.8–3.1) 2.3 (1.8–3.0) 0.018 0.087
HDL-C 1.0 (0.9–1.3) 1.3 (1.0–1.5) 1.8×10–11 1.8×10–10
HbA1c (mmol/mol) 43.9 (38–55) 48 (40–58.3) 0.0025 0.017
Hemoglobin (g/L) 140.7±13.3 - - -
White blood cell counts (×109/L) 7.8 (6.4–9.2) - - -
Platelet count (×109/L) 249 (207–298) - - -
CRP (mg/L) 3.9 (2.0–6.4) 1.4 (0.68–3.0) <1×10–16 <1×10–14
CD40 (A.U.‡) 3.2×107 (2.4×107–4.04×107) 9.1 (8.7–9.9) <1×10–16 <1×10–14
CD40L (A.U.‡) 1.8×105 (1.3×105–2.6×105) 6.8 (5.4–8.2) <1×10–16 <1×10–14
Values are presented as median (interquartile range) or mean±standard deviation. Categorical variables were compared using the chi-square test and continu-
ous variables by the Mann-Whitney U test or unpaired t-test (for non-normally and normally distributed samples, respectively).
CPIP, Carotid Plaque Imaging Project; SUMMIT, The SUrrogate markers for Micro- and Macro-vascular hard endpoints for Innovative diabetes Tools; LDL-C, 
low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; HbA1c, hemoglobin A1c; CRP, C-reactive protein; A.U., arbitrary unit; CD40L, 
CD40 ligand.
*P-value adjusted for multiple comparisons (according to the Holm-Šídák test); †Previous vascular intervention (percutaneous coronary intervention, coronary 
artery bypass grafting or drugs (statins, anticoagulant, beta-blocker, anti-hypertensive, renin-angiotensin-aldosterone system inhibitors); ‡In CPIP relative to 
plaque wet weight.
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Supplementary Table 3. Median with IQR values of sCD40 and sCD40L in plasma (A.U., SUMMIT cohort) when comparing between two groups (Mann-
Whitney U test)
CD40 (n=1,438) CD40L (n=1,438)
Content (A.U.) P, adjusted* Content (A.U.) P, adjusted
Female sex (vs. male sex) 9.16 (8.71–9.90) vs. 9.14 (8.70–9.89) 0.94 6.37 (5.04–8.06) vs. 6.99 (5.62–8.24) 0.0016
Diabetes type 2 (yes vs. no) 9.18 (8.74–9.91) vs. 9.08 (8.61–9.84) 0.016 6.94 (5.48–8.27) vs. 6.52 (5.17–8.02) 0.020
Stroke (yes vs. no)  9.75 (9.08–10.37 ) vs. 9.12 (8.70–9.80) 0.000030 7.88 (5.62–8.65) vs. 6.75 (5.37–8.16) 0.020
Hypertension (yes vs. no) 9.24 (8.73–9.95) vs. 8.98 (8.37–9.76) 0.00021 6.86 (5.39–8.21) vs. 6.63 (5.33–8.18) 0.51
AMI (yes vs. no) 9.27 (8.70–9.98) vs. 9.10 (8.70–9.82) 0.016 7.13 (5.47–8.24) vs. 6.71 (5.34–8.19) 0.28
IQR, interquartile range; sCD40, soluble CD40; sCD40L, soluble CD40 ligand; A.U., arbitrary unit; SUMMIT, The SUrrogate markers for Micro- and Macro-vas-
cular hard endpoints for Innovative diabetes Tools; AMI, acute myocardial infarction.
*P-value adjusted for multiple comparisons (according to the Holm-Šídák test).
Supplementary Table 4. Spearman correlations between the circulating levels of sCD40 and sCD40L (A.U., SUMMIT cohort) and change in IMT in the CCA 
and the carotid bulb region assessed by vascular ultrasound (at the 3-year follow-up point compared to study inclusion)
IMT change (mm)
CD40 
(n=1,438 at inclusion; n=798 at follow-up)
CD40L 
(n=1,438 at inclusion; n=798 at follow-up)
r P P, adjusted* r P P, adjusted
Right
Mean IMT in CCA –0.046 0.18 0.63 0.014 0.69 0.90
Max IMT in CCA 0.015 0.67 0.82 0.090 0.009 0.027
Mean IMT in bulb 0.027 0.44 0.82 0.149 0.000022 0.00011
Max IMT in bulb 0.075 0.034 0.21 0.243 3.65×10–12 2.55×10–11
Left
Mean IMT in CCA –0.039 0.25 0.68 0.014 0.69 0.90
Max IMT in CCA 0.051 0.14 0.59 0.115 0.001 0.0040
Mean IMT in bulb 0.025 0.47 0.82 0.233 1.66×10–10 9.96×10–10
Max IMT in bulb 0.092 0.009 0.070 0.261 7.86×10–14 6.29×10–13
sCD40, soluble CD40; sCD40L, soluble CD40 ligand; A.U., arbitrary unit; SUMMIT, The SUrrogate markers for Micro- and Macro-vascular hard endpoints for In-
novative diabetes Tools; IMT, intima-media thickness; CCA, common carotid artery.
*P-value adjusted for multiple comparisons.
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Supplementary Table 6. Spearman correlations of CD40 and CD40L (A.U., CPIP cohort) measured in plaque homogenate versus plaque elements
Variable
CD40 (n=198) CD40L (n=198)
r P P, adjusted r P P, adjusted
Plaque components (mg/g)
Collagen 0.248 0.00041 0.002 0.286 4.7×10–5 0.00052
Elastin 0.351 3.8×10–7 4.2×10–6 0.339 1.3×10–6 1.7×10–5
MMP1 0.262 0.00028 0.002 0.054 0.465 0.465
MMP2 0.254 0.00041 0.002 0.076 0.1 0.41
MMP9 0.249 0.0040 0.01 0.121 0.1 0.41
MMP10 0.373 1.3×10–7 1.7×10–6 0.373 0.003 0.021
TIMP1 0.363 4.2×10–7 4.2×10–6 0.204 0.006 0.035
TIMP2 0.326 6.1×10–6 5.5×10–5 0.307 2.5×10–5 0.0003
TIMP3 0.219 0.048 0.063 0.153 0.171  0.409
CD40L, CD40 ligand; A.U., arbitrary unit; CPIP, Carotid Plaque Imaging Project; MMP, matrix metalloproteinase; TIMP, tissue inhibitor of metalloproteinase.






Median 95% CI lower 95% CI upper Median 95% CI lower 95% CI upper
10% 0.060 0.980 0.953 1.000 0.110 0.093 0.128
20% 0.070 0.899 0.852 0.946 0.212 0.191 0.235
30% 0.077 0.826 0.765 0.886 0.315 0.289 0.342
40% 0.086 0.732 0.658 0.799 0.416 0.389 0.443
50% 0.097 0.664 0.584 0.738 0.520 0.493 0.546
60% 0.111 0.537 0.456 0.617 0.616 0.589 0.644
70% 0.123 0.450 0.369 0.530 0.717 0.692 0.743
80% 0.141 0.342 0.269 0.423 0.817 0.796 0.840
90% 0.176 0.208 0.148 0.282 0.913 0.898 0.929
Age and disease history (diabetes, hypertension, acute myocardial infarction, and stroke) at baseline were included in the LR model. Confidence intervals were 
calculated using a R package pROC with 2000 stratified bootstrap replicates.
CI, confidence interval; LR, logistic regression.
